Riociguat denied as experimental or investigational by Blue Cross Blue Shield?

Blue Cross Blue Shield's specific coverage criteria for riociguat are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why BCBS Denies Riociguat as Experimental or Investigational

An experimental or investigational denial means BCBS has determined that riociguat — or the specific use for which it was prescribed — does not meet the plan's definition of established, proven therapy. This can happen when: the drug is being used for an indication beyond its current FDA approval; BCBS's internal coverage criteria require additional evidence that was not submitted; or the plan's medical policy has not been updated to reflect current FDA approval status. Before appealing on the merits, confirm the current FDA approval status of riociguat for your specific indication at FDA's Drugs@FDA database, because an experimental denial for an FDA-approved indication is factually incorrect and should be reversed quickly.

## Why This Denial Is Appealable

For FDA-approved indications, an experimental denial is almost always incorrect as a matter of fact and plan contract. For off-label uses, many plans are required by state law or their own policy to cover off-label use that is supported by recognized medical compendia or peer-reviewed literature. Either way, federal appeal rights apply: - ACA §2719 / ERISA §503 require a full written internal appeal decision that specifically addresses the clinical and evidentiary basis of the experimental classification. - External review is available after internal denial; the window is generally up to approximately four months from the denial notice — verify the exact deadline on your Explanation of Benefits. - Expedited review is available when delay would jeopardize health, which is likely given the severity of pulmonary hypertension.

## Your Appeal Process and Timeline

1. Identify whether the prescribed indication is FDA-approved. If yes, attach the current FDA label and file a short appeal citing the factual error. 2. If the use is off-label, identify BCBS's off-label coverage policy and the compendia or guideline organizations (such as the relevant ACC/AHA or ERS/ESC guideline body) that support this use. 3. File the internal appeal. Request external review if denied.

## Documentation to Gather

• FDA prescribing information: current approved labeling for riociguat with indication text.
• Clinical records: diagnosis confirmation (right-heart catheterization data, imaging, functional classification) establishing the severity and type of pulmonary hypertension.
• Prescriber letter: specifically addressing the experimental classification, citing FDA approval status and relevant guideline support.
• Plan's experimental-coverage policy: to identify the exact evidentiary standard BCBS applies and show riociguat meets it.

## Criteria-Mapping Structure

Map BCBS's experimental-coverage criteria point by point. For each element (FDA approval, compendia listing, peer-reviewed evidence of safety and efficacy), identify the specific document that satisfies it. Where BCBS cited a specific deficiency in its denial letter, address that deficiency directly and explicitly.